



ajanta pharma limited

Ajanta House,
Charkop, Kandivli West,
Mumbai 400 067
India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

6th October, 2016

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find:

1. Quarterly Compliance Report on Corporate Governance (CG) for the quarter ended on 30th September, 2016; and
2. CG report for the half year ended 30th September 2016, in the prescribed format.

Thanking You,

Yours faithfully,

GAURANG SHAH
Sr. G.M. - Legal &
Company Secretary

Encl.: a/a

1. Name of Listed Entity : Ajanta Pharma Limited
 2. Half year ending : 30th September, 2016

Format to be submitted by listed entity at the end of 6 months after end of financial year along-with second quarter report of next financial year

I Affirmations	Regulation Number	Compliance status (Yes/No/NA)^{refer note below}
<i>Broad heading</i> Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website	46(2)	Yes except Business Responsibility Report (BRR) as it was not applicable for FY 2015-16. BRR is made applicable to our company from FY 2016-17 and as such BRR would be displayed on the website alongwith annual report for FY 2016-17.
<i>Presence of Chairperson of Audit Committee at the Annual General Meeting</i>	18(1)(d)	Yes
<i>Presence of Chairperson of the nomination and remuneration committee at the annual general meeting</i>	19(3)	Yes
<i>Whether "Corporate Governance Report" disclosed in Annual Report</i>	34(3) read with para C of Schedule V	Yes
Note		
1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.		
2 If status is "No" details of non-compliance may be given here.		
3 If the Listed Entity would like to provide any other information the same may be indicated here.		
Name & Designation : Mr. Gaurang Shah Company Secretary / Compliance Officer / Managing Director / CEO : Company Secretary & Compliance Officer		

For AJANTA PHARMA LIMITED

GAURANG SHAH
Sr. G.M. - Legal & Company Secretary

1. Name of Listed Entity : Ajanta Pharma Limited
 2. Quarter ending : 30th September, 2016

I. Composition of Board of Directors								
Title (Mr. / Ms)	Name of the Director	PAN ^S & DIN	Category (Chairperson /Executive/ Non-Executive/ independent / Nominee) [†]	Date of Appointment in the current term /cessation	Tenu re	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
“SAME AS PREVIOUS QUARTER”								
II. Composition of Committees								
“SAME AS PREVIOUS QUARTER”								
III. Meeting of Board of Directors								
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)	Maximum gap between any two consecutive (in number of days)				
29 th April, 2016	26 th July, 2016	26 th July, 2016	87 (excluding meeting days)	87 (excluding meeting days)				
IV. Meeting of Committees								
Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*	Maximum gap between any two consecutive meetings in number of days*				
Audit Committee: 26 th July, 2016	Yes, all the Committee members were present	29 th April, 2016	87 (excluding meeting days)	87 (excluding meeting days)				
Stakeholders' Relationship Committee: 26 th July, 2016	Yes, all the Committee members were present	29 th April, 2016	87 (excluding meeting days)	87 (excluding meeting days)				

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA)refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	NA
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes
VI. Affirmations	
1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.	
2. The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015	
a. Audit Committee	
b. Nomination & Remuneration committee	
c. Stakeholders relationship committee	
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
5. This report will be placed before Board of Directors at the ensuing Board meeting.	
Name & Designation : Gaurang C. Shah	
Company Secretary / Compliance Officer / Managing Director / CEO : Company Secretary & Compliance Officer	

For AJANTA PHARMA LIMITED


GAURANG SHAH

Sr. G.M. - Legal & Company Secretary